<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00095199</url>
  </required_header>
  <id_info>
    <org_study_id>13423</org_study_id>
    <secondary_id>I4E-MC-JXBC</secondary_id>
    <secondary_id>CP02-0452</secondary_id>
    <nct_id>NCT00095199</nct_id>
  </id_info>
  <brief_title>Docetaxel or Pemetrexed With or Without Cetuximab in Patients With Recurrent or Progressive Non-Small Cell Lung Cancer</brief_title>
  <official_title>Randomized Phase III Study of Docetaxel or Pemetrexed With or Without Cetuximab in Patients With Recurrent or Progressive Non-Small Cell Lung Cancer After Platinum-Based Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ImClone LLC</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial is a multicenter, open-label, randomized, Phase III study in patients with
      recurrent or progressive Non-Small Cell Lung Cancer (NSCLC) after failure of an initial
      platinum-based chemotherapy. Patients will receive either Docetaxel or Pemetrexed as
      chemotherapy at the investigator's choice. Within each chemotherapy group, patients will be
      randomized to receive Cetuximab plus chemotherapy or chemotherapy alone (Cetuximab &amp;
      Pemetrexed or Pemetrexed alone; Cetuximab &amp; Docetaxel or Docetaxel alone).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2005</start_date>
  <completion_date type="Actual">July 2011</completion_date>
  <primary_completion_date type="Actual">July 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>Randomization to progression of disease or death due to any cause up to 59.6 months</time_frame>
    <description>PFS was defined as the time from randomization until the date of progressive disease (PD) or death from any cause. Participants who were alive and without progression were censored at the date of their last tumor assessment. PFS was assessed by the independent review committee (IRC) in the Pemetrexed group (Cetuximab &amp; Pemetrexed versus Pemetrexed) and by the investigator in the Docetaxel group (Cetuximab &amp; Docetaxel versus Docetaxel).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Randomization to the date of death from any cause up to 72.8 months</time_frame>
    <description>OS was defined as the time from randomization to death. Participants without a date of death were censored on the last date participants were known to be alive, or lost to follow-up.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Randomized Participants With the Best Overall Response (OR) of Partial Response (PR) or Complete Response (CR) (Overall Response Rate [ORR])</measure>
    <time_frame>Randomization until progression of disease or death from any cause up to 59.6 months</time_frame>
    <description>The best overall response rate (ORR) was the proportion of randomized participants with a best OR of CR or PR, according to modified World Health Organization (WHO) guidelines. It was calculated as the total number of participants with CR or PR divided by the total number of participants treated in that arm. Participants with no post-baseline evaluation were considered as non-responders. The tumor response was assessed by the independent review committee (IRC) in the Pemetrexed group and by the investigator in the Docetaxel group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Randomized Participants With Best Overall Response (OR) of Partial Response (PR), Complete Response (CR), or Stable Disease (SD)</measure>
    <time_frame>Randomization to progression of disease or death due to any cause up to 59.6 months</time_frame>
    <description>The disease control rate (DCR) was the proportion of randomized participants with a best OR of CR, PR or SD according to modified World Health Organization (WHO) guidelines. It was calculated as the total number of participants with CR, PR or SD divided by the total number of participants randomized in that arm. The tumor response was assessed by the independent review committee (IRC) in the Pemetrexed group and by the investigator in the Docetaxel group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Symptomatic Response (Symptom Response Rates) Using the Lung Cancer Subscale (LCS) Scores of Functional Assessment of Cancer Therapy for Participants With Lung Cancer (FACT-L)</measure>
    <time_frame>At baseline, every 3 weeks and 30 days after end of therapy up to 50 months</time_frame>
    <description>The FACT-LCS is a set of 7 questions to inventory problems specific to lung cancer symptoms. Participants rate each item on a 5-point Likert-type scale from 0 (not at all) to 4 (very much). Scores range from 0-28 and higher score indicates fewer symptoms. Symptom response (improvement) was defined as ≥2 point increase from baseline in the 7-item LCS score that was maintained for 2 consecutive assessments at least 3 weeks, and not &gt;5 weeks apart for participants, whose baseline LCS score was ≤26. Symptom response rate was the percentage of participants with symptomatic response.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Symptomatic Progression</measure>
    <time_frame>Randomization until symptomatic progression up to 48.3 months</time_frame>
    <description>The FACT-LCS (see description in Outcome measure 5) inventories problems specific to lung cancer symptoms. Using this Scale, Symptom progression = a ≥ 2 point decrease from baseline in LCS score maintained for 2 consecutive assessments ≥3 weeks, and &lt;5 weeks, apart. The symptom progression date = the first of 2 consecutive assessments with a ≥2 point decline. Time to symptomatic progression = the time from randomization to the symptom progression date. For participants with no symptom progression, time to symptomatic progression was censored the date of last symptom assessment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Overall Response (OR)</measure>
    <time_frame>Time of first occurrence of either (PR) or (CR) to the first date of progressive disease or death up to 32.5 months</time_frame>
    <description>The duration of response, in participants with best OR of complete response (CR) or partial response (PR), was measured from the date criteria are met for CR/PR (not confirmation date, whichever was first recorded), until the first occurrence date that the criteria of progressive disease (PD) was met, or death. Participants who were alive and without progression were censored at the date of their last independent review committee (IRC) tumor assessment. The tumor response and progression were assessed by the IRC in the Pemetrexed group and by the investigator in the Docetaxel group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Common Toxicity Criteria (CTC) Grade 3 or 4 Toxicities</measure>
    <time_frame>Time from first dose to 30 days after last dose of study therapy up to 28.3 months for Cetuximab &amp; Pemetrexed (versus Pemetrexed alone) and up to 54.3 months for Cetuximab + Docetaxel (versus Docetaxel alone)</time_frame>
    <description>National Cancer Institutes-Common Toxicity Criteria version 3.0 was used by investigators to assess participant toxicities. Mapping of investigator verbatim terms to CTCAE terms was done by the sponsor/designee using CTCAE v4.0. Participants reported had grade 3 or 4 toxicities (or both potentially). Grade 3 AEs: severe or medically significant but not immediately life-threatening;hospitalization or prolongation of hospitalization indicated; disabling; limiting self care activities of daily living. Grade 4 AEs: life-threatening consequences; urgent intervention indicated.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">939</enrollment>
  <condition>Non Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Cetuximab &amp; Pemetrexed</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Pemetrexed</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cetuximab &amp; Docetaxel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Docetaxel</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pemetrexed</intervention_name>
    <description>Pemetrexed 500 mg/m^2 administered intravenously on Day 1 of 3 weeks cycle until disease progression or unacceptable toxicity for up to six (3-week) cycles.</description>
    <arm_group_label>Cetuximab &amp; Pemetrexed</arm_group_label>
    <arm_group_label>Pemetrexed</arm_group_label>
    <other_name>Alimta</other_name>
    <other_name>LY231514</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Cetuximab</intervention_name>
    <description>Cetuximab 400/250 mg/m^2 (initial/weekly) administered intravenously on Days 1, 8, and 15 (3-week) cycles until disease progression or unacceptable toxicity.</description>
    <arm_group_label>Cetuximab &amp; Pemetrexed</arm_group_label>
    <arm_group_label>Cetuximab &amp; Docetaxel</arm_group_label>
    <other_name>Erbitux</other_name>
    <other_name>LY2939777</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <description>Docetaxel 75 mg/m^2 administered intravenously on Day 1 of 3 weeks cycle until disease progression or unacceptable toxicity for up to six (3-week) cycles.</description>
    <arm_group_label>Cetuximab &amp; Docetaxel</arm_group_label>
    <arm_group_label>Docetaxel</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Pathologic confirmation of metastatic, unresectable, or locally-advanced NSCLC.

          -  Disease progression during or following one prior platinum-based chemotherapy regimen
             for advanced disease (stage IIIB or IV).

          -  Bidimensionally measurable disease.

          -  Karnofsky performance status score of 60 to 100 at study entry.

          -  The participant has tumor tissue available for immunohistochemical determination of
             epidermal growth factor (EGFR) expression.

          -  Adequate recovery from recent surgery, chemotherapy, and radiation therapy. At least 4
             weeks must have elapsed from major surgery, prior chemotherapy, prior treatment with
             an investigational agent, or prior radiation therapy (palliative radiation therapy is
             allowed).

          -  Accessible for treatment and follow-up. Participants enrolled in this trial must be
             treated at the participating center.

          -  Women of childbearing potential (WOCBP) and fertile men with partners of childbearing
             potential must be using an adequate method of contraception.

          -  WOCBP must have a negative serum or urine pregnancy test.

        Exclusion Criteria:

          -  Women who are pregnant or breastfeeding.

          -  Dementia, altered mental status, or any psychiatric condition that would prohibit the
             understanding or rendering of informed consent.

          -  A serious uncontrolled medical disorder that would impair the ability of the patient
             to receive protocol therapy.

          -  Symptomatic or uncontrolled metastases in the brain. Participants receiving a
             glucocorticoid for brain metastases will be excluded, but those receiving
             anticonvulsants will be eligible.

          -  Uncontrolled pleural effusion or ascites.

          -  Peripheral neuropathy greater than grade 2, as assessed by the National Cancer
             Institutes-Common Toxicity Criteria Adverse Events (NCI-CTCAE), Version 3.0.

          -  Any concurrent malignancy other than basal cell skin cancer, or carcinoma in situ of
             the cervix. Patients with a previous malignancy, but without evidence of disease for
             greater than or equal 3 years will be allowed to enter the trial.

          -  More than one prior chemotherapy regimen for advanced disease.

          -  Inadequate hematologic function defined by an absolute neutrophil count (ANC)
             &lt;1,500/mm3, a platelet count &lt;100,000/mm3, and a hemoglobin level &lt;9 g/dL. Red blood
             cell transfusions are not permitted within 7 days of receiving cetuximab, docetaxel,
             or pemetrexed.

          -  Inadequate hepatic function, defined by a total bilirubin level &gt;1.5 times the upper
             limit of normal (ULN), aspartate transaminase (AST) and alanine aminotransferase (ALT)
             levels &gt;2.5 times the ULN (greater than or equal to 5 times the ULN if known liver
             metastases), and an alkaline phosphatase level &gt;5.0 times the ULN.

          -  Inadequate renal function defined by a serum creatinine level &gt;1.5 times the ULN.

          -  Prior treatment with cetuximab, or any other epidermal growth factor receptor
             inhibitors, including tyrosine kinase inhibitors, such as gefitinib or erlotinib.
             Participants must not have received prior chimerized or murine monoclonal antibody
             therapy. Prior treatment with other monoclonal antibodies targeting receptors other
             than the EGFR is permitted &gt;30 days prior to randomization.

          -  Prior treatment with docetaxel or pemetrexed therapy.

          -  Inability or unwillingness to take folic acid or vitamin B12 supplementation.

          -  Inability or unwillingness to interrupt nonsteroidal anti-inflammatory drugs (NSAIDs)
             for a 5-day period (8-day period for long-acting agents such as piroxicam). Aspirin
             will be permitted during the study.

          -  Patients (including prisoners) who are compulsorily detained (involuntarily
             incarcerated) for treatment of either a psychiatric or physical (eg, infectious
             disease) illness.

          -  Prior treatment with an experimental drug or medical device within 30 days of
             randomization.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Montgomery</city>
        <state>Alabama</state>
        <zip>36106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85012</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85715</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Tuscon</city>
        <state>Arizona</state>
        <zip>85704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Greenbrae</city>
        <state>California</state>
        <zip>94904</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80218</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Stamford</city>
        <state>Connecticut</state>
        <zip>06902</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Trumbull</city>
        <state>Connecticut</state>
        <zip>06611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32256</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Lake Worth</city>
        <state>Florida</state>
        <zip>33461</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Athens</city>
        <state>Georgia</state>
        <zip>30607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30341</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60674</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46227</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67214</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Metairie</city>
        <state>Louisiana</state>
        <zip>70006</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Frederick</city>
        <state>Maryland</state>
        <zip>21701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Kalamazoo</city>
        <state>Michigan</state>
        <zip>49048</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Mount Clemens</city>
        <state>Michigan</state>
        <zip>48043</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>St Louis Park</city>
        <state>Minnesota</state>
        <zip>55416</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>St Joseph</city>
        <state>Missouri</state>
        <zip>64507</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Billings</city>
        <state>Montana</state>
        <zip>59101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89169</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Cherry Hill</city>
        <state>New Jersey</state>
        <zip>08003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14623</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Cary</city>
        <state>North Carolina</state>
        <zip>27518</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Concord</city>
        <state>North Carolina</state>
        <zip>28025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>High Point</city>
        <state>North Carolina</state>
        <zip>27262</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45267</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Eugene</city>
        <state>Oregon</state>
        <zip>97401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Dunmore</city>
        <state>Pennsylvania</state>
        <zip>18512</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Kingston</city>
        <state>Pennsylvania</state>
        <zip>18704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29605</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Hilton Head Island</city>
        <state>South Carolina</state>
        <zip>29926</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Mt. Pleasant</city>
        <state>South Carolina</state>
        <zip>29464</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38138</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Bedford</city>
        <state>Texas</state>
        <zip>76022</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Grapevine</city>
        <state>Texas</state>
        <zip>76051</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Mesquite</city>
        <state>Texas</state>
        <zip>75150</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Sugar Land</city>
        <state>Texas</state>
        <zip>77479</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Tyler</city>
        <state>Texas</state>
        <zip>75702</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Colchester</city>
        <state>Vermont</state>
        <zip>05446</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23249</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98133</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Vancouver</city>
        <state>Washington</state>
        <zip>98684</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 4N2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 4E6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 8L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2L 4M1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Sainte-Foy</city>
        <state>Quebec</state>
        <zip>G1V 4G2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>St-Jerome</city>
        <state>Quebec</state>
        <zip>J7Z 5T3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 1, 2004</study_first_submitted>
  <study_first_submitted_qc>November 1, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 2, 2004</study_first_posted>
  <results_first_submitted>June 19, 2012</results_first_submitted>
  <results_first_submitted_qc>September 13, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 15, 2012</results_first_posted>
  <last_update_submitted>September 13, 2012</last_update_submitted>
  <last_update_submitted_qc>September 13, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 15, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Recurrent or Progressive Non-Small Cell Lung Cancer</keyword>
  <keyword>Second-line therapy</keyword>
  <keyword>Docetaxel</keyword>
  <keyword>Pemetrexed</keyword>
  <keyword>Cetuximab</keyword>
  <keyword>Failed platinum-based therapy</keyword>
  <keyword>NSCLC</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Cetuximab</mesh_term>
    <mesh_term>Pemetrexed</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Although 939 participants were initially randomized, 1 participant's data was inadvertently lost by a site prior to being entered into the database. As a result, we are reporting 938 as randomized.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Cetuximab &amp; Pemetrexed</title>
          <description>Cetuximab 400/250 mg/m^2 (initial/weekly) administered intravenously on Days 1, 8, and 15 (3-week) cycles, until disease progression or unacceptable toxicity. Pemetrexed 500 mg/m^2 administered intravenously on day 1 of 3 weeks cycle until disease progression or unacceptable toxicity for up to six (3-week) cycles.</description>
        </group>
        <group group_id="P2">
          <title>Pemetrexed</title>
          <description>Pemetrexed 500 mg/m^2 administered intravenously on Day 1 of 3 week cycle for up to six (3-week) cycles.</description>
        </group>
        <group group_id="P3">
          <title>Cetuximab and Docetaxel</title>
          <description>Cetuximab 400/250 mg/m^2 (initial/weekly) administered intravenously on Days 1, 8, and 15 (3-week) cycles until disease progression or unacceptable toxicity. Docetaxel 75 mg/m^2 administered intravenously on Day 1 of 3 weeks cycle for up to six (3-week) cycles.</description>
        </group>
        <group group_id="P4">
          <title>Docetaxel</title>
          <description>Docetaxel 75 mg/m^2 administered intravenously on Day 1 of 3 weeks cycle until disease progression or unacceptable toxicity for up to six (3-week) cycles.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="302">1 participant has no data in database; not included in analyses. Data was lost/destroyed at site.</participants>
                <participants group_id="P2" count="304"/>
                <participants group_id="P3" count="167"/>
                <participants group_id="P4" count="166"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="62"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="23"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="296"/>
                <participants group_id="P2" count="242"/>
                <participants group_id="P3" count="160"/>
                <participants group_id="P4" count="143"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
                <participants group_id="P2" count="22"/>
                <participants group_id="P3" count="26"/>
                <participants group_id="P4" count="11"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Progressive disease</title>
              <participants_list>
                <participants group_id="P1" count="213"/>
                <participants group_id="P2" count="179"/>
                <participants group_id="P3" count="105"/>
                <participants group_id="P4" count="98"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="11"/>
                <participants group_id="P4" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="16"/>
                <participants group_id="P3" count="13"/>
                <participants group_id="P4" count="22"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Liver function test results elevated</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Surgery needed could not start in 7 days</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not eligible</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Started Palliative Radiotherapy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Started radiotherapy regimen</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Primary tumor removed in other surgery</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Data inadvertently lost by site</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Cetuximab &amp; Pemetrexed</title>
          <description>Cetuximab 400/250 mg/m^2 (initial/weekly) administered intravenously on Days 1, 8, and 15 (3-week) cycles until disease progression or unacceptable toxicity. Pemetrexed 500 mg/m^2 administered intravenously on Day 1 of 3 weeks cycle until disease progression or unacceptable toxicity for up to six (3-week) cycles.</description>
        </group>
        <group group_id="B2">
          <title>Pemetrexed</title>
          <description>Pemetrexed 500 mg/m^2 administered intravenously on Day 1 of 3 weeks cycle until disease progression or unacceptable toxicity for up to six (3-week) cycles.</description>
        </group>
        <group group_id="B3">
          <title>Cetuximab &amp; Docetaxel</title>
          <description>Cetuximab 400/250 mg/m^2 (initial/weekly) administered intravenously on Days 1, 8, and 15 (3-week) cycles until disease progression or unacceptable toxicity. Docetaxel 75 mg/m^2 administered intravenously on Day 1 of 3 weeks cycle for up to six (3-week) cycles.</description>
        </group>
        <group group_id="B4">
          <title>Docetaxel</title>
          <description>Docetaxel 75 mg/m^2 administered intravenously on Day 1 of 3 weeks cycle until disease progression or unacceptable toxicity for up to six (3-week) cycles.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="301"/>
            <count group_id="B2" value="304"/>
            <count group_id="B3" value="167"/>
            <count group_id="B4" value="166"/>
            <count group_id="B5" value="938"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62.8" spread="10.0"/>
                    <measurement group_id="B2" value="64.0" spread="9.4"/>
                    <measurement group_id="B3" value="63.6" spread="9.4"/>
                    <measurement group_id="B4" value="63.9" spread="9.2"/>
                    <measurement group_id="B5" value="63.5" spread="9.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="128"/>
                    <measurement group_id="B2" value="116"/>
                    <measurement group_id="B3" value="75"/>
                    <measurement group_id="B4" value="73"/>
                    <measurement group_id="B5" value="392"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="173"/>
                    <measurement group_id="B2" value="188"/>
                    <measurement group_id="B3" value="92"/>
                    <measurement group_id="B4" value="93"/>
                    <measurement group_id="B5" value="546"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="268"/>
                    <measurement group_id="B2" value="265"/>
                    <measurement group_id="B3" value="146"/>
                    <measurement group_id="B4" value="141"/>
                    <measurement group_id="B5" value="820"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="20"/>
                    <measurement group_id="B5" value="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="265"/>
                    <measurement group_id="B2" value="270"/>
                    <measurement group_id="B3" value="152"/>
                    <measurement group_id="B4" value="151"/>
                    <measurement group_id="B5" value="838"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="15"/>
                    <measurement group_id="B4" value="15"/>
                    <measurement group_id="B5" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Epidermal growth factor receptor (EGFR) by immunohistochemistry</title>
          <description>Immunohistochemical staining intensity of anti-EGFR antibody: Score 0=No staining is observed in membrane; Score +1=Staining in membrane is partial, weak and barely perceptible; Score +2=Staining is weak but is completely observed in membrane; Score +3=Strong complete membrane staining is observed. EGFR positive staining is a potential prognostic factor in non-small cell lung cancer. Presence of EGFR staining was not, however, an inclusion criteria or used to stratify participants in the trial.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>+1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                    <measurement group_id="B2" value="35"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="19"/>
                    <measurement group_id="B5" value="103"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>+2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46"/>
                    <measurement group_id="B2" value="53"/>
                    <measurement group_id="B3" value="26"/>
                    <measurement group_id="B4" value="34"/>
                    <measurement group_id="B5" value="159"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>+3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="118"/>
                    <measurement group_id="B2" value="108"/>
                    <measurement group_id="B3" value="72"/>
                    <measurement group_id="B4" value="58"/>
                    <measurement group_id="B5" value="356"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="32"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B5" value="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="80"/>
                    <measurement group_id="B2" value="76"/>
                    <measurement group_id="B3" value="44"/>
                    <measurement group_id="B4" value="45"/>
                    <measurement group_id="B5" value="245"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Karnofsky Performance Status</title>
          <description>Karnofsky performance status was part of eligibility criteria and classifies participants according to their functional impairment. Scores range from 0-100, the lower the score, the worse the survival for most serious illnesses. 100=Normal. No complaints. No evidence of disease; 90=Able to carry on normal activity. Minor signs of disease; 80=Activity with effort. Some signs of disease; 70=Unable to carry on normal activity or to do active work; 60=Requires occasional assistance, but is able to care for most needs; &lt;60=Needs increasing assistance, up to a score of 0=death.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>60</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="11"/>
                    <measurement group_id="B5" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>70</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="35"/>
                    <measurement group_id="B3" value="21"/>
                    <measurement group_id="B4" value="14"/>
                    <measurement group_id="B5" value="105"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>80</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="103"/>
                    <measurement group_id="B2" value="91"/>
                    <measurement group_id="B3" value="55"/>
                    <measurement group_id="B4" value="57"/>
                    <measurement group_id="B5" value="306"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>90</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="101"/>
                    <measurement group_id="B2" value="116"/>
                    <measurement group_id="B3" value="74"/>
                    <measurement group_id="B4" value="64"/>
                    <measurement group_id="B5" value="355"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>100</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48"/>
                    <measurement group_id="B2" value="47"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="18"/>
                    <measurement group_id="B5" value="127"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing/unknown</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Pathological Diagnosis</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Adenocarcinoma</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="161"/>
                    <measurement group_id="B2" value="185"/>
                    <measurement group_id="B3" value="99"/>
                    <measurement group_id="B4" value="83"/>
                    <measurement group_id="B5" value="528"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Large cell carcinoma</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>All other non-squamous diagnoses</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                    <measurement group_id="B2" value="41"/>
                    <measurement group_id="B3" value="20"/>
                    <measurement group_id="B4" value="29"/>
                    <measurement group_id="B5" value="135"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Squamous cell carcinoma</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="76"/>
                    <measurement group_id="B2" value="71"/>
                    <measurement group_id="B3" value="41"/>
                    <measurement group_id="B4" value="51"/>
                    <measurement group_id="B5" value="239"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Progression Free Survival (PFS)</title>
        <description>PFS was defined as the time from randomization until the date of progressive disease (PD) or death from any cause. Participants who were alive and without progression were censored at the date of their last tumor assessment. PFS was assessed by the independent review committee (IRC) in the Pemetrexed group (Cetuximab &amp; Pemetrexed versus Pemetrexed) and by the investigator in the Docetaxel group (Cetuximab &amp; Docetaxel versus Docetaxel).</description>
        <time_frame>Randomization to progression of disease or death due to any cause up to 59.6 months</time_frame>
        <population>The intent-to-treat population (ITT) included all participants classified according to the treatment arms into which they were randomized, regardless of the actual treatment received. Censored participants: 10 in Cetuximab + Pemetrexed arm; 25 in Pemetrexed arm; 6 in Cetuximab + Docetaxel arm; 16 in Docetaxel arm.</population>
        <group_list>
          <group group_id="O1">
            <title>Cetuximab &amp; Pemetrexed</title>
            <description>Cetuximab 400/250 mg/m^2 (initial/weekly) administered intravenously on Days 1, 8, and 15 (3-week) cycles until disease progression or unacceptable toxicity. Pemetrexed 500 mg/m^2 administered intravenously on Day 1 of 3 weeks cycle until disease progression or unacceptable toxicity for up to six (3-week cycles).</description>
          </group>
          <group group_id="O2">
            <title>Pemetrexed</title>
            <description>Pemetrexed 500 mg/m^2 administered intravenously on Day 1 of 3 weeks cycle for up to six (3-week) cycles.</description>
          </group>
          <group group_id="O3">
            <title>Cetuximab &amp; Docetaxel</title>
            <description>Cetuximab 400/250 mg/m^2 (initial/weekly) administered intravenously every 3 weeks cycle for up to six (3-week) cycles, after 6 cycles participants on the chemotherapy/cetuximab combination may continue cetuximab alone. Docetaxel 75 mg/m^2 administered intravenously on Day 1 of 3 weeks cycle for up to six (3-week) cycles.</description>
          </group>
          <group group_id="O4">
            <title>Docetaxel</title>
            <description>Docetaxel 75 mg/m^2 administered intravenously on Day 1 of 3 weeks cycle for up to six (3-week) cycles.</description>
          </group>
        </group_list>
        <measure>
          <title>Progression Free Survival (PFS)</title>
          <description>PFS was defined as the time from randomization until the date of progressive disease (PD) or death from any cause. Participants who were alive and without progression were censored at the date of their last tumor assessment. PFS was assessed by the independent review committee (IRC) in the Pemetrexed group (Cetuximab &amp; Pemetrexed versus Pemetrexed) and by the investigator in the Docetaxel group (Cetuximab &amp; Docetaxel versus Docetaxel).</description>
          <population>The intent-to-treat population (ITT) included all participants classified according to the treatment arms into which they were randomized, regardless of the actual treatment received. Censored participants: 10 in Cetuximab + Pemetrexed arm; 25 in Pemetrexed arm; 6 in Cetuximab + Docetaxel arm; 16 in Docetaxel arm.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="301"/>
                <count group_id="O2" value="304"/>
                <count group_id="O3" value="167"/>
                <count group_id="O4" value="166"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.89" lower_limit="2.69" upper_limit="3.22"/>
                    <measurement group_id="O2" value="2.76" lower_limit="2.53" upper_limit="3.29"/>
                    <measurement group_id="O3" value="2.37" lower_limit="1.61" upper_limit="2.89"/>
                    <measurement group_id="O4" value="1.54" lower_limit="1.45" upper_limit="2.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The Pemetrexed comparisons (Cetuximab + Pemetrexed vs Pemetrexed) were considered the primary comparisons. The Docetaxel comparisons (Cetuximab + Docetaxel vs Docetaxel) were considered supportive as Docetaxel comparisons remained underpowered by design. No tests were conducted to compare participants who received Docetaxel to those who received Pemetrexed.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.756</p_value>
            <p_value_desc>The 2-sided unstratified log-rank test was employed at the 5% significance level.</p_value_desc>
            <method>Log Rank</method>
            <method_desc>Kaplan-Meier method estimated median PFS time. HR was calculated with unstratified Cox proportional hazards model. HR&lt;1 favours Cetuximab arm</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.03</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.87</ci_lower_limit>
            <ci_upper_limit>1.21</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The Pemetrexed comparisons (Cetuximab + Pemetrexed vs Pemetrexed) were considered the primary comparisons. The Docetaxel comparisons (Cetuximab + Docetaxel vs Docetaxel) were considered supportive as Docetaxel comparisons remained underpowered by design. No tests were conducted to compare participants who received Docetaxel to those who received Pemetrexed.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.391</p_value>
            <p_value_desc>The 2-sided unstratified log-rank test was employed at the 5% significance level.</p_value_desc>
            <method>Log Rank</method>
            <method_desc>Kaplan-Meier method estimated median PFS time. HR was calculated with unstratified Cox proportional hazards model. HR&lt;1 favours Cetuximab arm</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.91</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.73</ci_lower_limit>
            <ci_upper_limit>1.13</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival (OS)</title>
        <description>OS was defined as the time from randomization to death. Participants without a date of death were censored on the last date participants were known to be alive, or lost to follow-up.</description>
        <time_frame>Randomization to the date of death from any cause up to 72.8 months</time_frame>
        <population>The intent-to-treat population (ITT) included all participants classified according to the treatment arms into which they were randomized, regardless of the actual treatment received. Censored participants: 24 in Cetuximab + Pemetrexed arm; 43 in Pemetrexed arm; 12 in Cetuximab + Docetaxel arm; 22 in Docetaxel arm.</population>
        <group_list>
          <group group_id="O1">
            <title>Cetuximab &amp; Pemetrexed</title>
            <description>Cetuximab 400/250 mg/m^2 (initial/weekly) administered intravenously on Days 1, 8, and 15 (3-week) cycles until disease progression or unacceptable toxicity. Pemetrexed 500 mg/m^2 administered intravenously on Day 1 of 3 weeks cycle until disease progression or unacceptable toxicity for up to six (3-week) cycles.</description>
          </group>
          <group group_id="O2">
            <title>Pemetrexed</title>
            <description>Pemetrexed 500 mg/m^2 administered intravenously on Day 1 of 3 weeks cycle for up to six (3-week) cycles.</description>
          </group>
          <group group_id="O3">
            <title>Cetuximab &amp; Docetaxel</title>
            <description>Cetuximab 400/250 mg/m^2 (initial/weekly) administered intravenously every 3 weeks cycle for up to six (3-week) cycles, after 6 cycles participants on the chemotherapy/cetuximab combination may continue cetuximab alone. Docetaxel 75 mg/m^2 administered intravenously on Day 1 of 3 weeks cycle for up to six (3-week) cycles.</description>
          </group>
          <group group_id="O4">
            <title>Docetaxel</title>
            <description>Docetaxel 75 mg/m^2 administered intravenously on Day 1 of 3 weeks cycle for up to six (3-week) cycles.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival (OS)</title>
          <description>OS was defined as the time from randomization to death. Participants without a date of death were censored on the last date participants were known to be alive, or lost to follow-up.</description>
          <population>The intent-to-treat population (ITT) included all participants classified according to the treatment arms into which they were randomized, regardless of the actual treatment received. Censored participants: 24 in Cetuximab + Pemetrexed arm; 43 in Pemetrexed arm; 12 in Cetuximab + Docetaxel arm; 22 in Docetaxel arm.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="301"/>
                <count group_id="O2" value="304"/>
                <count group_id="O3" value="167"/>
                <count group_id="O4" value="166"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.93" lower_limit="6.28" upper_limit="7.85"/>
                    <measurement group_id="O2" value="7.79" lower_limit="6.77" upper_limit="8.41"/>
                    <measurement group_id="O3" value="5.75" lower_limit="4.73" upper_limit="8.31"/>
                    <measurement group_id="O4" value="8.15" lower_limit="6.11" upper_limit="9.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The Pemetrexed comparisons (Cetuximab + Pemetrexed vs Pemetrexed) were considered the primary comparisons. The Docetaxel comparisons (Cetuximab + Docetaxel vs Docetaxel) were considered supportive as Docetaxel comparisons remained underpowered by design. No tests were conducted to compare participants who received Docetaxel to those who received Pemetrexed.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.864</p_value>
            <p_value_desc>The 2-sided unstratified log-rank test was employed at the 5% significance level</p_value_desc>
            <method>Log Rank</method>
            <method_desc>Kaplan-Meier method estimated median OS time. HR was calculated with unstratified Cox proportional hazards model. HR&lt;1 favors Cetuximab arm</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.01</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.86</ci_lower_limit>
            <ci_upper_limit>1.20</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The Pemetrexed comparisons (Cetuximab + Pemetrexed vs Pemetrexed) were considered the primary comparisons. The Docetaxel comparisons (Cetuximab + Docetaxel vs Docetaxel) were considered supportive as Docetaxel comparisons remained underpowered by design. No tests were conducted to compare participants who received Docetaxel to those who received Pemetrexed.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.307</p_value>
            <p_value_desc>The 2-sided unstratified log-rank test was employed at the 5% significance level.</p_value_desc>
            <method>Log Rank</method>
            <method_desc>Kaplan-Meier method estimated median OS time. HR was calculated with unstratified Cox proportional hazards model. HR&lt;1 favors Cetuximab arm</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.13</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.90</ci_lower_limit>
            <ci_upper_limit>1.41</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Randomized Participants With the Best Overall Response (OR) of Partial Response (PR) or Complete Response (CR) (Overall Response Rate [ORR])</title>
        <description>The best overall response rate (ORR) was the proportion of randomized participants with a best OR of CR or PR, according to modified World Health Organization (WHO) guidelines. It was calculated as the total number of participants with CR or PR divided by the total number of participants treated in that arm. Participants with no post-baseline evaluation were considered as non-responders. The tumor response was assessed by the independent review committee (IRC) in the Pemetrexed group and by the investigator in the Docetaxel group.</description>
        <time_frame>Randomization until progression of disease or death from any cause up to 59.6 months</time_frame>
        <population>The intent-to-treat population (ITT) included all participants classified according to the treatment arms into which they were randomized, regardless of the actual treatment received.</population>
        <group_list>
          <group group_id="O1">
            <title>Cetuximab &amp; Pemetrexed</title>
            <description>Cetuximab 400/250 mg/m^2 (initial/weekly) administered intravenously on Days 1, 8, and 15 (3-week) cycles until disease progression or unacceptable toxicity. Pemetrexed 500 mg/m^2 administered intravenously on Day 1 of 3 weeks cycle until disease progression or unacceptable toxicity for up to six (3-week) cycles.</description>
          </group>
          <group group_id="O2">
            <title>Pemetrexed</title>
            <description>Pemetrexed 500 mg/m^2 administered intravenously on Day 1 of 3 weeks cycle for up to six (3-week) cycles.</description>
          </group>
          <group group_id="O3">
            <title>Cetuximab &amp; Docetaxel</title>
            <description>Cetuximab 400/250 mg/m^2 (initial/weekly) administered intravenously every 3 weeks cycle for up to six (3-week) cycles, after 6 cycles participants on the chemotherapy/cetuximab combination may continue cetuximab alone. Docetaxel 75 mg/m^2 administered intravenously on Day 1 of 3 weeks cycle for up to six (3-week) cycles.</description>
          </group>
          <group group_id="O4">
            <title>Docetaxel</title>
            <description>Docetaxel 75 mg/m^2 administered intravenously on Day 1 of 3 weeks cycle for up to six (3-week) cycles.</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Randomized Participants With the Best Overall Response (OR) of Partial Response (PR) or Complete Response (CR) (Overall Response Rate [ORR])</title>
          <description>The best overall response rate (ORR) was the proportion of randomized participants with a best OR of CR or PR, according to modified World Health Organization (WHO) guidelines. It was calculated as the total number of participants with CR or PR divided by the total number of participants treated in that arm. Participants with no post-baseline evaluation were considered as non-responders. The tumor response was assessed by the independent review committee (IRC) in the Pemetrexed group and by the investigator in the Docetaxel group.</description>
          <population>The intent-to-treat population (ITT) included all participants classified according to the treatment arms into which they were randomized, regardless of the actual treatment received.</population>
          <units>proportion of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="301"/>
                <count group_id="O2" value="304"/>
                <count group_id="O3" value="167"/>
                <count group_id="O4" value="166"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.066" lower_limit="0.038" upper_limit="0.095"/>
                    <measurement group_id="O2" value="0.043" lower_limit="0.020" upper_limit="0.066"/>
                    <measurement group_id="O3" value="0.078" lower_limit="0.037" upper_limit="0.118"/>
                    <measurement group_id="O4" value="0.066" lower_limit="0.028" upper_limit="0.104"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The Pemetrexed comparisons (Cetuximab + Pemetrexed vs Pemetrexed) were considered the primary comparisons. The Docetaxel comparisons (Cetuximab + Docetaxel vs Docetaxel) were considered supportive as Docetaxel comparisons remained underpowered by design. No tests were conducted to compare participants who received Docetaxel to those who received Pemetrexed.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.200</p_value>
            <p_value_desc>The 2-sided unstratified Mantel Haenszel test was employed at the 5% significance level.</p_value_desc>
            <method>Mantel Haenszel</method>
            <method_desc>HR&lt;1 favors Cetuximab arm</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.59</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.78</ci_lower_limit>
            <ci_upper_limit>3.26</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The Pemetrexed comparisons (Cetuximab + Pemetrexed vs Pemetrexed) were considered the primary comparisons. The Docetaxel comparisons (Cetuximab + Docetaxel vs Docetaxel) were considered supportive as Docetaxel comparisons remained underpowered by design. No tests were conducted to compare participants who received Docetaxel to those who received Pemetrexed.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.683</p_value>
            <p_value_desc>The 2-sided unstratified Mantel Haenszel test was employed at the 5% significance level.</p_value_desc>
            <method>Mantel Haenszel</method>
            <method_desc>HR&lt;1 favors Cetuximab arm</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.19</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.52</ci_lower_limit>
            <ci_upper_limit>2.74</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Randomized Participants With Best Overall Response (OR) of Partial Response (PR), Complete Response (CR), or Stable Disease (SD)</title>
        <description>The disease control rate (DCR) was the proportion of randomized participants with a best OR of CR, PR or SD according to modified World Health Organization (WHO) guidelines. It was calculated as the total number of participants with CR, PR or SD divided by the total number of participants randomized in that arm. The tumor response was assessed by the independent review committee (IRC) in the Pemetrexed group and by the investigator in the Docetaxel group.</description>
        <time_frame>Randomization to progression of disease or death due to any cause up to 59.6 months</time_frame>
        <population>The intent-to-treat population (ITT) included all participants classified according to the treatment arms into which they were randomized, regardless of the actual treatment received.</population>
        <group_list>
          <group group_id="O1">
            <title>Cetuximab &amp; Pemetrexed</title>
            <description>Cetuximab 400/250 mg/m^2 (initial/weekly) administered intravenously on Days 1, 8, and 15 (3-week) cycles until disease progression or unacceptable toxicity. Pemetrexed 500 mg/m^2 administered intravenously on Day 1 of 3 weeks cycle until disease progression or unacceptable toxicity for up to six (3-week cycles).</description>
          </group>
          <group group_id="O2">
            <title>Pemetrexed</title>
            <description>Pemetrexed 500 mg/m^2 administered intravenously on Day 1 of 3 weeks cycle for up to six (3-week) cycles.</description>
          </group>
          <group group_id="O3">
            <title>Cetuximab &amp; Docetaxel</title>
            <description>Cetuximab 400/250 mg/m^2 (initial/weekly) administered intravenously every 3 weeks cycle for up to six (3-week) cycles, after 6 cycles participants on the chemotherapy/cetuximab combination may continue cetuximab alone. Docetaxel 75 mg/m^2 administered intravenously on Day 1 of 3 weeks cycle for up to six (3-week) cycles.</description>
          </group>
          <group group_id="O4">
            <title>Docetaxel</title>
            <description>Docetaxel 75 mg/m^2 administered intravenously on Day 1 of 3 weeks cycle for up to six (3-week) cycles.</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Randomized Participants With Best Overall Response (OR) of Partial Response (PR), Complete Response (CR), or Stable Disease (SD)</title>
          <description>The disease control rate (DCR) was the proportion of randomized participants with a best OR of CR, PR or SD according to modified World Health Organization (WHO) guidelines. It was calculated as the total number of participants with CR, PR or SD divided by the total number of participants randomized in that arm. The tumor response was assessed by the independent review committee (IRC) in the Pemetrexed group and by the investigator in the Docetaxel group.</description>
          <population>The intent-to-treat population (ITT) included all participants classified according to the treatment arms into which they were randomized, regardless of the actual treatment received.</population>
          <units>proportion of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="301"/>
                <count group_id="O2" value="304"/>
                <count group_id="O3" value="167"/>
                <count group_id="O4" value="166"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.522" lower_limit="0.465" upper_limit="0.578"/>
                    <measurement group_id="O2" value="0.480" lower_limit="0.424" upper_limit="0.536"/>
                    <measurement group_id="O3" value="0.335" lower_limit="0.264" upper_limit="0.407"/>
                    <measurement group_id="O4" value="0.253" lower_limit="0.187" upper_limit="0.319"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The Pemetrexed comparisons (Cetuximab + Pemetrexed vs Pemetrexed) were considered the primary comparisons. The Docetaxel comparisons (Cetuximab + Docetaxel vs Docetaxel) were considered supportive as Docetaxel comparisons remained underpowered by design. No tests were conducted to compare participants who received Docetaxel to those who received Pemetrexed.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.310</p_value>
            <p_value_desc>The 2-sided unstratified Mantel Haenszel test was employed at the 5% significance level.</p_value_desc>
            <method>Mantel Haenszel</method>
            <method_desc>HR&lt;1 favors Cetuximab arm</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.18</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.86</ci_lower_limit>
            <ci_upper_limit>1.62</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The Pemetrexed comparisons (Cetuximab + Pemetrexed vs Pemetrexed) were considered the primary comparisons. The Docetaxel comparisons (Cetuximab + Docetaxel vs Docetaxel) were considered supportive as Docetaxel comparisons remained underpowered by design. No tests were conducted to compare participants who received Docetaxel to those who received Pemetrexed.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.100</p_value>
            <p_value_desc>The 2-sided unstratified Mantel Haenszel test was employed at the 5% significance level.</p_value_desc>
            <method>Mantel Haenszel</method>
            <method_desc>HR&lt;1 favors Cetuximab arm</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.49</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.93</ci_lower_limit>
            <ci_upper_limit>2.40</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Symptomatic Response (Symptom Response Rates) Using the Lung Cancer Subscale (LCS) Scores of Functional Assessment of Cancer Therapy for Participants With Lung Cancer (FACT-L)</title>
        <description>The FACT-LCS is a set of 7 questions to inventory problems specific to lung cancer symptoms. Participants rate each item on a 5-point Likert-type scale from 0 (not at all) to 4 (very much). Scores range from 0-28 and higher score indicates fewer symptoms. Symptom response (improvement) was defined as ≥2 point increase from baseline in the 7-item LCS score that was maintained for 2 consecutive assessments at least 3 weeks, and not &gt;5 weeks apart for participants, whose baseline LCS score was ≤26. Symptom response rate was the percentage of participants with symptomatic response.</description>
        <time_frame>At baseline, every 3 weeks and 30 days after end of therapy up to 50 months</time_frame>
        <population>The randomized participants with baseline LCS scores less than or equal to 26.</population>
        <group_list>
          <group group_id="O1">
            <title>Cetuximab &amp; Pemetrexed</title>
            <description>Cetuximab 400/250 mg/m^2 (initial/weekly) administered intravenously on Days 1, 8, and 15 (3-week) cycles until disease progression or unacceptable toxicity. Pemetrexed 500 mg/m^2 administered intravenously on Day 1 of 3 weeks cycle until disease progression or unacceptable toxicity for up to six (3-week) cycles.</description>
          </group>
          <group group_id="O2">
            <title>Pemetrexed</title>
            <description>Pemetrexed 500 mg/m^2 administered intravenously on Day 1 of 3 weeks cycle for up to six (3-week) cycles.</description>
          </group>
          <group group_id="O3">
            <title>Cetuximab &amp; Docetaxel</title>
            <description>Cetuximab 400/250 mg/m^2 (initial/weekly) administered intravenously every 3 weeks cycle for up to six (3-week) cycles, after 6 cycles participants on the chemotherapy/cetuximab combination may continue cetuximab alone. Docetaxel 75 mg/m^2 administered intravenously on Day 1 of 3 weeks cycle for up to six (3-week) cycles.</description>
          </group>
          <group group_id="O4">
            <title>Docetaxel</title>
            <description>Docetaxel 75 mg/m^2 administered intravenously on Day 1 of 3 weeks cycle for up to six (3-week) cycles.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Symptomatic Response (Symptom Response Rates) Using the Lung Cancer Subscale (LCS) Scores of Functional Assessment of Cancer Therapy for Participants With Lung Cancer (FACT-L)</title>
          <description>The FACT-LCS is a set of 7 questions to inventory problems specific to lung cancer symptoms. Participants rate each item on a 5-point Likert-type scale from 0 (not at all) to 4 (very much). Scores range from 0-28 and higher score indicates fewer symptoms. Symptom response (improvement) was defined as ≥2 point increase from baseline in the 7-item LCS score that was maintained for 2 consecutive assessments at least 3 weeks, and not &gt;5 weeks apart for participants, whose baseline LCS score was ≤26. Symptom response rate was the percentage of participants with symptomatic response.</description>
          <population>The randomized participants with baseline LCS scores less than or equal to 26.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="280"/>
                <count group_id="O2" value="280"/>
                <count group_id="O3" value="150"/>
                <count group_id="O4" value="155"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.1" lower_limit="12.7" upper_limit="21.6"/>
                    <measurement group_id="O2" value="22.9" lower_limit="17.9" upper_limit="27.8"/>
                    <measurement group_id="O3" value="17.3" lower_limit="11.3" upper_limit="23.4"/>
                    <measurement group_id="O4" value="13.5" lower_limit="8.2" upper_limit="18.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The Pemetrexed comparisons (Cetuximab + Pemetrexed vs Pemetrexed) were considered the primary comparisons. The Docetaxel comparisons (Cetuximab + Docetaxel vs Docetaxel) were considered supportive as Docetaxel comparisons remained underpowered by design. No tests were conducted to compare participants who received Docetaxel to those who received Pemetrexed.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.091</p_value>
            <p_value_desc>The 2-sided unstratified Mantel Haenszel test was employed at the 5% significance level.</p_value_desc>
            <method>Mantel Haenszel</method>
            <method_desc>HR&lt;1 favors Cetuximab arm</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.70</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.46</ci_lower_limit>
            <ci_upper_limit>1.06</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The Pemetrexed comparisons (Cetuximab + Pemetrexed vs Pemetrexed) were considered the primary comparisons. The Docetaxel comparisons (Cetuximab + Docetaxel vs Docetaxel) were considered supportive as Docetaxel comparisons remained underpowered by design. No tests were conducted to compare participants who received Docetaxel to those who received Pemetrexed.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.361</p_value>
            <p_value_desc>The 2-sided unstratified Mantel Haenszel test was employed at the 5% significance level.</p_value_desc>
            <method>Mantel Haenszel</method>
            <method_desc>HR&lt;1 favors Cetuximab arm</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.34</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.72</ci_lower_limit>
            <ci_upper_limit>2.50</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Symptomatic Progression</title>
        <description>The FACT-LCS (see description in Outcome measure 5) inventories problems specific to lung cancer symptoms. Using this Scale, Symptom progression = a ≥ 2 point decrease from baseline in LCS score maintained for 2 consecutive assessments ≥3 weeks, and &lt;5 weeks, apart. The symptom progression date = the first of 2 consecutive assessments with a ≥2 point decline. Time to symptomatic progression = the time from randomization to the symptom progression date. For participants with no symptom progression, time to symptomatic progression was censored the date of last symptom assessment.</description>
        <time_frame>Randomization until symptomatic progression up to 48.3 months</time_frame>
        <population>All randomized participants with a baseline LCS &gt;= 2 were included. Censored participants: 237 in Cetuximab plus Pemetrexed arm; 244 in Pemetrexed arm; 126 in Cetuximab plus Docetaxel arm; 131 in Docetaxel arm.</population>
        <group_list>
          <group group_id="O1">
            <title>Cetuximab &amp; Pemetrexed</title>
            <description>Cetuximab 400/250 mg/m^2 (initial/weekly) administered intravenously on Days 1, 8, and 15 (3-week) cycles until disease progression or unacceptable toxicity. Pemetrexed 500 mg/m^2 administered intravenously on Day 1 of 3 weeks cycle until disease progression or unacceptable toxicity for up to six (3-week) cycles.</description>
          </group>
          <group group_id="O2">
            <title>Pemetrexed</title>
            <description>Pemetrexed 500 mg/m^2 administered intravenously on Day 1 of 3 weeks cycle for up to six (3-week) cycles.</description>
          </group>
          <group group_id="O3">
            <title>Cetuximab &amp; Docetaxel</title>
            <description>Cetuximab 400/250 mg/m^2 (initial/weekly) administered intravenously every 3 weeks cycle for up to six (3-week cycles), after 6 cycles participants on the chemotherapy/cetuximab combination may continue cetuximab alone. Docetaxel 75 mg/m^2 administered intravenously on Day 1 of 3 weeks cycle for up to six (3-week) cycles.</description>
          </group>
          <group group_id="O4">
            <title>Docetaxel</title>
            <description>Docetaxel 75 mg/m^2 administered intravenously on Day 1 of 3 weeks cycle for up to six (3-week) cycles.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Symptomatic Progression</title>
          <description>The FACT-LCS (see description in Outcome measure 5) inventories problems specific to lung cancer symptoms. Using this Scale, Symptom progression = a ≥ 2 point decrease from baseline in LCS score maintained for 2 consecutive assessments ≥3 weeks, and &lt;5 weeks, apart. The symptom progression date = the first of 2 consecutive assessments with a ≥2 point decline. Time to symptomatic progression = the time from randomization to the symptom progression date. For participants with no symptom progression, time to symptomatic progression was censored the date of last symptom assessment.</description>
          <population>All randomized participants with a baseline LCS &gt;= 2 were included. Censored participants: 237 in Cetuximab plus Pemetrexed arm; 244 in Pemetrexed arm; 126 in Cetuximab plus Docetaxel arm; 131 in Docetaxel arm.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="289"/>
                <count group_id="O2" value="287"/>
                <count group_id="O3" value="152"/>
                <count group_id="O4" value="158"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">The median time to symptomatic progression is not estimable because the probability of symptomatic progression free never decreased to 0.5</measurement>
                    <measurement group_id="O2" value="NA">The median time to symptomatic progression is not estimable because the probability of symptomatic progression free never decreased to 0.5</measurement>
                    <measurement group_id="O3" value="NA" lower_limit="7.00">The median time to symptomatic progression is not estimable because the probability of symptomatic progression free never decreased to 0.5</measurement>
                    <measurement group_id="O4" value="NA">The median time to symptomatic progression is not estimable because the probability of symptomatic progression free never decreased to 0.5</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The Pemetrexed comparisons (Cetuximab + Pemetrexed vs Pemetrexed) were considered the primary comparisons. The Docetaxel comparisons (Cetuximab + Docetaxel vs Docetaxel) were considered supportive as Docetaxel comparisons remained underpowered by design. No tests were conducted to compare participants who received Docetaxel to those who received Pemetrexed.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.472</p_value>
            <p_value_desc>The 2-sided unstratified log-rank test was employed at the 5% significance level.</p_value_desc>
            <method>Log Rank</method>
            <method_desc>Kaplan-Meier estimated time to symptomatic progression. HR was calculated using unstratified Cox proportional hazards model. HR&lt;1 favors Cetuximab arm</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.16</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.77</ci_lower_limit>
            <ci_upper_limit>1.74</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The Pemetrexed comparisons (Cetuximab + Pemetrexed vs Pemetrexed) were considered the primary comparisons. The Docetaxel comparisons (Cetuximab + Docetaxel vs Docetaxel) were considered supportive as Docetaxel comparisons remained underpowered by design. No tests were conducted to compare participants who received Docetaxel to those who received Pemetrexed.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.272</p_value>
            <p_value_desc>The 2-sided unstratified log-rank test was employed at the 5% significance level.</p_value_desc>
            <method>Log Rank</method>
            <method_desc>Kaplan-Meier estimated time to symptomatic progression. HR was calculated using unstratified Cox proportional hazards model. HR&lt;1 favors Cetuximab arm</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.73</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.42</ci_lower_limit>
            <ci_upper_limit>1.27</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Overall Response (OR)</title>
        <description>The duration of response, in participants with best OR of complete response (CR) or partial response (PR), was measured from the date criteria are met for CR/PR (not confirmation date, whichever was first recorded), until the first occurrence date that the criteria of progressive disease (PD) was met, or death. Participants who were alive and without progression were censored at the date of their last independent review committee (IRC) tumor assessment. The tumor response and progression were assessed by the IRC in the Pemetrexed group and by the investigator in the Docetaxel group.</description>
        <time_frame>Time of first occurrence of either (PR) or (CR) to the first date of progressive disease or death up to 32.5 months</time_frame>
        <population>All randomized participants with a best overall response of CR or PR. Censored participants: 1 in Cetuximab plus Pemetrexed arm; 2 in Pemetrexed arm; 1 in Cetuximab plus Docetaxel arm; 0 in Docetaxel arm.</population>
        <group_list>
          <group group_id="O1">
            <title>Cetuximab &amp; Pemetrexed</title>
            <description>Cetuximab 400/250 mg/m^2 (initial/weekly) administered intravenously on Days 1, 8, and 15 (3-week) cycles until disease progression or unacceptable toxicity. Pemetrexed 500 mg/m^2 administered intravenously on Day 1 of 3 weeks cycle until disease progression or unacceptable toxicity for up to six (3-week cycles).</description>
          </group>
          <group group_id="O2">
            <title>Pemetrexed</title>
            <description>Pemetrexed 500 mg/m^2 administered intravenously on Day 1 of 3 weeks cycle for up to six (3-week) cycles.</description>
          </group>
          <group group_id="O3">
            <title>Cetuximab &amp; Docetaxel</title>
            <description>Cetuximab 400/250 mg/m2 (initial/weekly) administered intravenously every 3 weeks cycle for up to six (3-week) cycles, after 6 cycles participants on the chemotherapy/cetuximab combination may continue cetuximab alone. Docetaxel 75 mg/m^2 administered intravenously on Day 1 of 3 weeks cycle for up to six (3-week cycles).</description>
          </group>
          <group group_id="O4">
            <title>Docetaxel</title>
            <description>Docetaxel 75 mg/m^2 administered intravenously on Day 1 of 3 weeks cycle for up to six (3-week) cycles.</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Overall Response (OR)</title>
          <description>The duration of response, in participants with best OR of complete response (CR) or partial response (PR), was measured from the date criteria are met for CR/PR (not confirmation date, whichever was first recorded), until the first occurrence date that the criteria of progressive disease (PD) was met, or death. Participants who were alive and without progression were censored at the date of their last independent review committee (IRC) tumor assessment. The tumor response and progression were assessed by the IRC in the Pemetrexed group and by the investigator in the Docetaxel group.</description>
          <population>All randomized participants with a best overall response of CR or PR. Censored participants: 1 in Cetuximab plus Pemetrexed arm; 2 in Pemetrexed arm; 1 in Cetuximab plus Docetaxel arm; 0 in Docetaxel arm.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="13"/>
                <count group_id="O4" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.17" lower_limit="2.92" upper_limit="5.45"/>
                    <measurement group_id="O2" value="6.93" lower_limit="3.98" upper_limit="16.36"/>
                    <measurement group_id="O3" value="5.36" lower_limit="2.73" upper_limit="6.93"/>
                    <measurement group_id="O4" value="5.39" lower_limit="3.12" upper_limit="7.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The Pemetrexed comparisons (Cetuximab + Pemetrexed vs Pemetrexed) were considered the primary comparisons. The Docetaxel comparisons (Cetuximab + Docetaxel vs Docetaxel) were considered supportive as Docetaxel comparisons remained underpowered by design. No tests were conducted to compare participants who received Docetaxel to those who received Pemetrexed.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.236</p_value>
            <p_value_desc>The 2-sided unstratified log-rank test was employed at the 5% significance level.</p_value_desc>
            <method>Log Rank</method>
            <method_desc>The Kaplan-Meier method estimated duration of response. HR was calculated using unstratified Cox proportional hazards model. HR&lt;1 favors Cetuximab arm</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.58</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.74</ci_lower_limit>
            <ci_upper_limit>3.36</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The Pemetrexed comparisons (Cetuximab + Pemetrexed vs Pemetrexed) were considered the primary comparisons. The Docetaxel comparisons (Cetuximab + Docetaxel vs Docetaxel) were considered supportive as Docetaxel comparisons remained underpowered by design. No tests were conducted to compare participants who received Docetaxel to those who received Pemetrexed.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.887</p_value>
            <p_value_desc>The 2-sided unstratified log-rank test was employed at the 5% significance level.</p_value_desc>
            <method>Log Rank</method>
            <method_desc>The Kaplan-Meier method estimated duration of response. HR was calculated using unstratified Cox proportional hazards model. HR&lt;1 favors Cetuximab arm</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.96</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.42</ci_lower_limit>
            <ci_upper_limit>2.18</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Common Toxicity Criteria (CTC) Grade 3 or 4 Toxicities</title>
        <description>National Cancer Institutes-Common Toxicity Criteria version 3.0 was used by investigators to assess participant toxicities. Mapping of investigator verbatim terms to CTCAE terms was done by the sponsor/designee using CTCAE v4.0. Participants reported had grade 3 or 4 toxicities (or both potentially). Grade 3 AEs: severe or medically significant but not immediately life-threatening;hospitalization or prolongation of hospitalization indicated; disabling; limiting self care activities of daily living. Grade 4 AEs: life-threatening consequences; urgent intervention indicated.</description>
        <time_frame>Time from first dose to 30 days after last dose of study therapy up to 28.3 months for Cetuximab &amp; Pemetrexed (versus Pemetrexed alone) and up to 54.3 months for Cetuximab + Docetaxel (versus Docetaxel alone)</time_frame>
        <population>All randomized participants receiving at least 1 dose of study drug made up the safety population for this outcome measure. Investigators graded events using CTCAE v3.0. Mapping of investigator verbatim terms for toxicity to CTCAE terms was done by the sponsor/designee using CTCAE v4.0.</population>
        <group_list>
          <group group_id="O1">
            <title>Cetuximab &amp; Pemetrexed</title>
            <description>Cetuximab 400/250 mg/m^2 (initial/weekly) administered intravenously on Days 1, 8, and 15 (3-week cycles) until disease progression or unacceptable toxicity. Pemetrexed 500 mg/m^2 administered intravenously on Day 1 of 3 weeks cycle until disease progression or unacceptable toxicity for up to six (3-week) cycles.</description>
          </group>
          <group group_id="O2">
            <title>Pemetrexed</title>
            <description>Pemetrexed 500 mg/m^2 administered intravenously on Day 1 of 3 weeks cycle for up to six (3-week) cycles.</description>
          </group>
          <group group_id="O3">
            <title>Cetuximab + Docetaxel</title>
            <description>Cetuximab 400/250 mg/m^2 (initial/weekly) administered intravenously on Day 1 of every 3 weeks cycle for up to six (3-week) cycles, after 6 cycles participants on the chemotherapy/cetuximab combination may continue cetuximab alone. Docetaxel 75 mg/m2 administered intravenously on Day 1 of 3 week cycle for up to six (3-week) cycles.</description>
          </group>
          <group group_id="O4">
            <title>Docetaxel</title>
            <description>Docetaxel 75 mg/m^2 administered intravenously on Day 1 of 3 weeks cycle for up to six (3-week) cycles.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Common Toxicity Criteria (CTC) Grade 3 or 4 Toxicities</title>
          <description>National Cancer Institutes-Common Toxicity Criteria version 3.0 was used by investigators to assess participant toxicities. Mapping of investigator verbatim terms to CTCAE terms was done by the sponsor/designee using CTCAE v4.0. Participants reported had grade 3 or 4 toxicities (or both potentially). Grade 3 AEs: severe or medically significant but not immediately life-threatening;hospitalization or prolongation of hospitalization indicated; disabling; limiting self care activities of daily living. Grade 4 AEs: life-threatening consequences; urgent intervention indicated.</description>
          <population>All randomized participants receiving at least 1 dose of study drug made up the safety population for this outcome measure. Investigators graded events using CTCAE v3.0. Mapping of investigator verbatim terms for toxicity to CTCAE terms was done by the sponsor/designee using CTCAE v4.0.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="292"/>
                <count group_id="O2" value="289"/>
                <count group_id="O3" value="159"/>
                <count group_id="O4" value="149"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="179"/>
                    <measurement group_id="O2" value="143"/>
                    <measurement group_id="O3" value="112"/>
                    <measurement group_id="O4" value="97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Randomization to 30 days after study therapy up to 72.8 months for Cetuximab &amp; Pemetrexed (versus just Pemetrexed) and up to 64.3 months for Cetuximab + Docetaxel (versus just Docetaxel)</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Cetuximab &amp; Pemetrexed</title>
          <description>Cetuximab 400/250 mg/m^2 (initial/weekly) administered intravenously on Days 1, 8, and 15 (3-week) cycles, until disease progression or unacceptable toxicity. Pemetrexed 500 mg/m^2 administered intravenously on day 1 of 3 weeks cycle until disease progression or unacceptable toxicity for up to six (3-week) cycles.</description>
        </group>
        <group group_id="E2">
          <title>Pemetrexed</title>
          <description>Pemetrexed 500 mg/m^2 administered intravenously on Day 1 of 3 week cycle for up to six (3-week) cycles.</description>
        </group>
        <group group_id="E3">
          <title>Cetuximab and Docetaxel</title>
          <description>Cetuximab 400/250 mg/m^2 (initial/weekly) administered intravenously on Days 1, 8, and 15 (3-week) cycles until disease progression or unacceptable toxicity. Docetaxel 75 mg/m^2 administered intravenously on Day 1 of 3 weeks cycle for up to six (3-week) cycles.</description>
        </group>
        <group group_id="E4">
          <title>Docetaxel</title>
          <description>Docetaxel 75 mg/m^2 administered intravenously on Day 1 of 3 weeks cycle until disease progression or unacceptable toxicity for up to six (3-week) cycles.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 14.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="119" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="86" subjects_at_risk="289"/>
                <counts group_id="E3" subjects_affected="84" subjects_at_risk="159"/>
                <counts group_id="E4" subjects_affected="60" subjects_at_risk="149"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="292"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="289"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="159"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Coagulopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="292"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="292"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="289"/>
                <counts group_id="E3" events="14" subjects_affected="13" subjects_at_risk="159"/>
                <counts group_id="E4" events="11" subjects_affected="11" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Hypercoagulation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="292"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Leukocytosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="289"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="159"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="292"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="289"/>
                <counts group_id="E3" events="11" subjects_affected="10" subjects_at_risk="159"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Pancytopenia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="292"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="289"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="292"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="289"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="149"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="292"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="12" subjects_affected="10" subjects_at_risk="292"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="289"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E4" events="7" subjects_affected="5" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="292"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="289"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Atrial tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="292"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="292"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="292"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="159"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Cardiac tamponade</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="292"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Cardio-respiratory arrest</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="292"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Left ventricular dysfunction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="292"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="292"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="292"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="292"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="292"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="289"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E4" events="3" subjects_affected="2" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Sinus tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="292"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Ventricular fibrillation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Ventricular tachycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="292"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="149"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="292"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="289"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Caecitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="159"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="292"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="289"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="289"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="159"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Diverticular perforation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="292"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="289"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Gastric haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Gastric ulcer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="292"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Gastritis erosive</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="292"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="292"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Gastrointestinal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="292"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="292"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E3" events="4" subjects_affected="3" subjects_at_risk="159"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Oesophageal ulcer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="292"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="292"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="292"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="289"/>
                <counts group_id="E3" events="7" subjects_affected="6" subjects_at_risk="159"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="149"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="292"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="159"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="292"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="292"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Disease progression</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="292"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="289"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="159"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="292"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="159"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Hypothermia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Impaired healing</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="292"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Multi-organ failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="292"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="289"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Oedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="292"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="159"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="292"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="289"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="159"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="292"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="289"/>
                <counts group_id="E3" events="10" subjects_affected="10" subjects_at_risk="159"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Sudden death</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Systemic inflammatory response syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="149"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="292"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="159"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="149"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abdominal infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="292"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Bacteraemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="292"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="292"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Catheter site infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="292"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="289"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Cellulitis staphylococcal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="292"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Clostridial infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Empyema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="292"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Gangrene</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="292"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Incision site infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="292"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="292"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Lobar pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="292"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Lung infection pseudomonal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Meningitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Necrotising fasciitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Oral candidiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Pelvic abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Peridiverticular abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="292"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="16" subjects_affected="16" subjects_at_risk="292"/>
                <counts group_id="E2" events="17" subjects_affected="17" subjects_at_risk="289"/>
                <counts group_id="E3" events="11" subjects_affected="9" subjects_at_risk="159"/>
                <counts group_id="E4" events="10" subjects_affected="10" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Pneumonia klebsiella</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Postoperative wound infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="292"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="292"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="159"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Sepsis syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="292"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="292"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="159"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Staphylococcal bacteraemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="292"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Staphylococcal sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Subcutaneous abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="292"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="149"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Collapse of lung</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="292"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Femoral neck fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="292"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="292"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Infusion related reaction</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="292"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Overdose</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="292"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Pneumonitis chemical</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Sternal fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="292"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Toxicity to various agents</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="292"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Traumatic lung injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="149"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Activated partial thromboplastin time prolonged</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Haemoglobin decreased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="292"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>International normalised ratio increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="292"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="292"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="149"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="289"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="292"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="289"/>
                <counts group_id="E3" events="19" subjects_affected="17" subjects_at_risk="159"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Electrolyte imbalance</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="292"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Failure to thrive</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Hypercalcaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="292"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="292"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Hypomagnesaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="292"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="292"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Hypophosphataemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="292"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Hypovolaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="292"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Metabolic acidosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="292"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="149"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="292"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="289"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="292"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Mobility decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="292"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="289"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Pain in jaw</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="149"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Malignant pleural effusion</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="292"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Metastases to bone</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Metastases to central nervous system</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Neoplasm malignant</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="292"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Non-small cell lung cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Ovarian cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="149"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Ataxia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="292"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Brain injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="292"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Brain stem haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="292"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="292"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Cerebral ischaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="292"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="289"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Cognitive disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="292"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="289"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="159"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Depressed level of consciousness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="292"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="292"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Dysarthria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Dyskinesia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="292"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Hemiparesis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="292"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Hydrocephalus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="292"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Neuropathy peripheral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="292"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Partial seizures</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Speech disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Spinal cord compression</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="292"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="149"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="292"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="289"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="159"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Delirium</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="292"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Disorientation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Drug abuse</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="292"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Mental status changes</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="292"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Schizoaffective disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="292"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="149"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Pollakiuria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="292"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="292"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="292"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="289"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="159"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Renal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="292"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="149"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute respiratory distress syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="292"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="292"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Apnoeic attack</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="292"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="292"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Bronchial haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Bronchospasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="292"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="289"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E4" events="4" subjects_affected="3" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="289"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="18" subjects_affected="14" subjects_at_risk="292"/>
                <counts group_id="E2" events="14" subjects_affected="11" subjects_at_risk="289"/>
                <counts group_id="E3" events="13" subjects_affected="12" subjects_at_risk="159"/>
                <counts group_id="E4" events="8" subjects_affected="6" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="292"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="292"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="289"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="159"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Hydropneumothorax</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Hypercapnia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="292"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="289"/>
                <counts group_id="E3" events="5" subjects_affected="4" subjects_at_risk="159"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Interstitial lung disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="292"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="159"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" events="11" subjects_affected="9" subjects_at_risk="292"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="289"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="159"/>
                <counts group_id="E4" events="10" subjects_affected="7" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Pneumonia aspiration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="292"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="292"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="159"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="292"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="289"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="159"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Pulmonary fibrosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="292"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Respiratory arrest</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Respiratory distress</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="292"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="289"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="292"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="289"/>
                <counts group_id="E3" events="8" subjects_affected="7" subjects_at_risk="159"/>
                <counts group_id="E4" events="6" subjects_affected="3" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Respiratory tract haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="149"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Angioedema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="292"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Dermatitis acneiform</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="292"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Purpura</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="292"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="149"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Leg amputation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="292"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Pain management</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="292"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Ventriculo-peritoneal shunt</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="292"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="149"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="292"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" events="8" subjects_affected="8" subjects_at_risk="159"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Exsanguination</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="292"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="292"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" events="6" subjects_affected="5" subjects_at_risk="159"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Ischaemic limb pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="292"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Orthostatic hypotension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="292"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Peripheral ischaemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="292"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Superior vena cava syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="292"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="292"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="149"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 14.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="289" subjects_at_risk="292"/>
                <counts group_id="E2" subjects_affected="281" subjects_at_risk="289"/>
                <counts group_id="E3" subjects_affected="159" subjects_at_risk="159"/>
                <counts group_id="E4" subjects_affected="147" subjects_at_risk="149"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="90" subjects_affected="70" subjects_at_risk="292"/>
                <counts group_id="E2" events="93" subjects_affected="64" subjects_at_risk="289"/>
                <counts group_id="E3" events="75" subjects_affected="40" subjects_at_risk="159"/>
                <counts group_id="E4" events="48" subjects_affected="35" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" events="14" subjects_affected="10" subjects_at_risk="292"/>
                <counts group_id="E2" events="17" subjects_affected="11" subjects_at_risk="289"/>
                <counts group_id="E3" events="31" subjects_affected="15" subjects_at_risk="159"/>
                <counts group_id="E4" events="13" subjects_affected="7" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="51" subjects_affected="32" subjects_at_risk="292"/>
                <counts group_id="E2" events="58" subjects_affected="32" subjects_at_risk="289"/>
                <counts group_id="E3" events="121" subjects_affected="74" subjects_at_risk="159"/>
                <counts group_id="E4" events="95" subjects_affected="46" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="26" subjects_affected="14" subjects_at_risk="292"/>
                <counts group_id="E2" events="48" subjects_affected="22" subjects_at_risk="289"/>
                <counts group_id="E3" events="11" subjects_affected="7" subjects_at_risk="159"/>
                <counts group_id="E4" events="7" subjects_affected="2" subjects_at_risk="149"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" events="16" subjects_affected="13" subjects_at_risk="292"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="289"/>
                <counts group_id="E3" events="15" subjects_affected="15" subjects_at_risk="159"/>
                <counts group_id="E4" events="8" subjects_affected="8" subjects_at_risk="149"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Lacrimation increased</sub_title>
                <counts group_id="E1" events="21" subjects_affected="20" subjects_at_risk="292"/>
                <counts group_id="E2" events="16" subjects_affected="16" subjects_at_risk="289"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="159"/>
                <counts group_id="E4" events="7" subjects_affected="7" subjects_at_risk="149"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="22" subjects_affected="19" subjects_at_risk="292"/>
                <counts group_id="E2" events="19" subjects_affected="16" subjects_at_risk="289"/>
                <counts group_id="E3" events="16" subjects_affected="15" subjects_at_risk="159"/>
                <counts group_id="E4" events="7" subjects_affected="6" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="18" subjects_affected="16" subjects_at_risk="292"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="289"/>
                <counts group_id="E3" events="9" subjects_affected="4" subjects_at_risk="159"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="94" subjects_affected="75" subjects_at_risk="292"/>
                <counts group_id="E2" events="66" subjects_affected="60" subjects_at_risk="289"/>
                <counts group_id="E3" events="48" subjects_affected="41" subjects_at_risk="159"/>
                <counts group_id="E4" events="27" subjects_affected="25" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="108" subjects_affected="81" subjects_at_risk="292"/>
                <counts group_id="E2" events="38" subjects_affected="36" subjects_at_risk="289"/>
                <counts group_id="E3" events="91" subjects_affected="63" subjects_at_risk="159"/>
                <counts group_id="E4" events="28" subjects_affected="22" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="26" subjects_affected="21" subjects_at_risk="292"/>
                <counts group_id="E2" events="16" subjects_affected="15" subjects_at_risk="289"/>
                <counts group_id="E3" events="16" subjects_affected="12" subjects_at_risk="159"/>
                <counts group_id="E4" events="7" subjects_affected="7" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="146" subjects_affected="112" subjects_at_risk="292"/>
                <counts group_id="E2" events="128" subjects_affected="89" subjects_at_risk="289"/>
                <counts group_id="E3" events="68" subjects_affected="53" subjects_at_risk="159"/>
                <counts group_id="E4" events="48" subjects_affected="38" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Oral pain</sub_title>
                <counts group_id="E1" events="12" subjects_affected="11" subjects_at_risk="292"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="289"/>
                <counts group_id="E3" events="8" subjects_affected="8" subjects_at_risk="159"/>
                <counts group_id="E4" events="8" subjects_affected="7" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" events="78" subjects_affected="54" subjects_at_risk="292"/>
                <counts group_id="E2" events="21" subjects_affected="21" subjects_at_risk="289"/>
                <counts group_id="E3" events="74" subjects_affected="53" subjects_at_risk="159"/>
                <counts group_id="E4" events="26" subjects_affected="23" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="83" subjects_affected="59" subjects_at_risk="292"/>
                <counts group_id="E2" events="54" subjects_affected="44" subjects_at_risk="289"/>
                <counts group_id="E3" events="32" subjects_affected="25" subjects_at_risk="159"/>
                <counts group_id="E4" events="22" subjects_affected="19" subjects_at_risk="149"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="40" subjects_affected="37" subjects_at_risk="292"/>
                <counts group_id="E2" events="42" subjects_affected="33" subjects_at_risk="289"/>
                <counts group_id="E3" events="41" subjects_affected="29" subjects_at_risk="159"/>
                <counts group_id="E4" events="20" subjects_affected="15" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" events="14" subjects_affected="12" subjects_at_risk="292"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="289"/>
                <counts group_id="E3" events="12" subjects_affected="9" subjects_at_risk="159"/>
                <counts group_id="E4" events="16" subjects_affected="15" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="209" subjects_affected="158" subjects_at_risk="292"/>
                <counts group_id="E2" events="191" subjects_affected="133" subjects_at_risk="289"/>
                <counts group_id="E3" events="146" subjects_affected="88" subjects_at_risk="159"/>
                <counts group_id="E4" events="99" subjects_affected="74" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="292"/>
                <counts group_id="E2" events="22" subjects_affected="18" subjects_at_risk="289"/>
                <counts group_id="E3" events="7" subjects_affected="6" subjects_at_risk="159"/>
                <counts group_id="E4" events="9" subjects_affected="7" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" events="70" subjects_affected="51" subjects_at_risk="292"/>
                <counts group_id="E2" events="35" subjects_affected="32" subjects_at_risk="289"/>
                <counts group_id="E3" events="28" subjects_affected="23" subjects_at_risk="159"/>
                <counts group_id="E4" events="28" subjects_affected="27" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="20" subjects_affected="12" subjects_at_risk="292"/>
                <counts group_id="E2" events="15" subjects_affected="14" subjects_at_risk="289"/>
                <counts group_id="E3" events="12" subjects_affected="10" subjects_at_risk="159"/>
                <counts group_id="E4" events="12" subjects_affected="11" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="60" subjects_affected="46" subjects_at_risk="292"/>
                <counts group_id="E2" events="43" subjects_affected="37" subjects_at_risk="289"/>
                <counts group_id="E3" events="29" subjects_affected="22" subjects_at_risk="159"/>
                <counts group_id="E4" events="14" subjects_affected="14" subjects_at_risk="149"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Candidiasis</sub_title>
                <counts group_id="E1" events="13" subjects_affected="11" subjects_at_risk="292"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="289"/>
                <counts group_id="E3" events="9" subjects_affected="8" subjects_at_risk="159"/>
                <counts group_id="E4" events="6" subjects_affected="6" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Oral candidiasis</sub_title>
                <counts group_id="E1" events="11" subjects_affected="9" subjects_at_risk="292"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="289"/>
                <counts group_id="E3" events="13" subjects_affected="10" subjects_at_risk="159"/>
                <counts group_id="E4" events="7" subjects_affected="5" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Paronychia</sub_title>
                <counts group_id="E1" events="21" subjects_affected="15" subjects_at_risk="292"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" events="6" subjects_affected="3" subjects_at_risk="159"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="20" subjects_affected="18" subjects_at_risk="292"/>
                <counts group_id="E2" events="10" subjects_affected="9" subjects_at_risk="289"/>
                <counts group_id="E3" events="9" subjects_affected="8" subjects_at_risk="159"/>
                <counts group_id="E4" events="7" subjects_affected="6" subjects_at_risk="149"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Infusion related reaction</sub_title>
                <counts group_id="E1" events="19" subjects_affected="15" subjects_at_risk="292"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" events="5" subjects_affected="4" subjects_at_risk="159"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="149"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" events="25" subjects_affected="19" subjects_at_risk="292"/>
                <counts group_id="E2" events="15" subjects_affected="15" subjects_at_risk="289"/>
                <counts group_id="E3" events="20" subjects_affected="18" subjects_at_risk="159"/>
                <counts group_id="E4" events="8" subjects_affected="7" subjects_at_risk="149"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="102" subjects_affected="86" subjects_at_risk="292"/>
                <counts group_id="E2" events="63" subjects_affected="58" subjects_at_risk="289"/>
                <counts group_id="E3" events="68" subjects_affected="54" subjects_at_risk="159"/>
                <counts group_id="E4" events="47" subjects_affected="45" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="28" subjects_affected="27" subjects_at_risk="292"/>
                <counts group_id="E2" events="21" subjects_affected="17" subjects_at_risk="289"/>
                <counts group_id="E3" events="28" subjects_affected="24" subjects_at_risk="159"/>
                <counts group_id="E4" events="26" subjects_affected="14" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" events="14" subjects_affected="11" subjects_at_risk="292"/>
                <counts group_id="E2" events="28" subjects_affected="20" subjects_at_risk="289"/>
                <counts group_id="E3" events="7" subjects_affected="6" subjects_at_risk="159"/>
                <counts group_id="E4" events="6" subjects_affected="4" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" events="33" subjects_affected="29" subjects_at_risk="292"/>
                <counts group_id="E2" events="12" subjects_affected="11" subjects_at_risk="289"/>
                <counts group_id="E3" events="32" subjects_affected="26" subjects_at_risk="159"/>
                <counts group_id="E4" events="5" subjects_affected="4" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Hypomagnesaemia</sub_title>
                <counts group_id="E1" events="91" subjects_affected="57" subjects_at_risk="292"/>
                <counts group_id="E2" events="20" subjects_affected="17" subjects_at_risk="289"/>
                <counts group_id="E3" events="55" subjects_affected="36" subjects_at_risk="159"/>
                <counts group_id="E4" events="6" subjects_affected="6" subjects_at_risk="149"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="18" subjects_affected="16" subjects_at_risk="292"/>
                <counts group_id="E2" events="23" subjects_affected="22" subjects_at_risk="289"/>
                <counts group_id="E3" events="18" subjects_affected="14" subjects_at_risk="159"/>
                <counts group_id="E4" events="18" subjects_affected="17" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="44" subjects_affected="36" subjects_at_risk="292"/>
                <counts group_id="E2" events="16" subjects_affected="14" subjects_at_risk="289"/>
                <counts group_id="E3" events="19" subjects_affected="17" subjects_at_risk="159"/>
                <counts group_id="E4" events="8" subjects_affected="7" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" events="12" subjects_affected="10" subjects_at_risk="292"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="289"/>
                <counts group_id="E3" events="12" subjects_affected="9" subjects_at_risk="159"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" events="12" subjects_affected="11" subjects_at_risk="292"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="289"/>
                <counts group_id="E3" events="11" subjects_affected="10" subjects_at_risk="159"/>
                <counts group_id="E4" events="7" subjects_affected="6" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" events="22" subjects_affected="19" subjects_at_risk="292"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="289"/>
                <counts group_id="E3" events="9" subjects_affected="7" subjects_at_risk="159"/>
                <counts group_id="E4" events="6" subjects_affected="6" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" events="13" subjects_affected="11" subjects_at_risk="292"/>
                <counts group_id="E2" events="14" subjects_affected="13" subjects_at_risk="289"/>
                <counts group_id="E3" events="9" subjects_affected="8" subjects_at_risk="159"/>
                <counts group_id="E4" events="9" subjects_affected="9" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="25" subjects_affected="14" subjects_at_risk="292"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="289"/>
                <counts group_id="E3" events="23" subjects_affected="21" subjects_at_risk="159"/>
                <counts group_id="E4" events="19" subjects_affected="14" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="25" subjects_affected="21" subjects_at_risk="292"/>
                <counts group_id="E2" events="16" subjects_affected="16" subjects_at_risk="289"/>
                <counts group_id="E3" events="14" subjects_affected="11" subjects_at_risk="159"/>
                <counts group_id="E4" events="6" subjects_affected="6" subjects_at_risk="149"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="49" subjects_affected="41" subjects_at_risk="292"/>
                <counts group_id="E2" events="18" subjects_affected="14" subjects_at_risk="289"/>
                <counts group_id="E3" events="26" subjects_affected="21" subjects_at_risk="159"/>
                <counts group_id="E4" events="22" subjects_affected="18" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" events="25" subjects_affected="25" subjects_at_risk="292"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="289"/>
                <counts group_id="E3" events="30" subjects_affected="23" subjects_at_risk="159"/>
                <counts group_id="E4" events="13" subjects_affected="13" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="28" subjects_affected="20" subjects_at_risk="292"/>
                <counts group_id="E2" events="22" subjects_affected="21" subjects_at_risk="289"/>
                <counts group_id="E3" events="8" subjects_affected="8" subjects_at_risk="159"/>
                <counts group_id="E4" events="16" subjects_affected="15" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Neuropathy peripheral</sub_title>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="292"/>
                <counts group_id="E2" events="15" subjects_affected="15" subjects_at_risk="289"/>
                <counts group_id="E3" events="18" subjects_affected="16" subjects_at_risk="159"/>
                <counts group_id="E4" events="15" subjects_affected="13" subjects_at_risk="149"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="22" subjects_affected="20" subjects_at_risk="292"/>
                <counts group_id="E2" events="18" subjects_affected="16" subjects_at_risk="289"/>
                <counts group_id="E3" events="8" subjects_affected="8" subjects_at_risk="159"/>
                <counts group_id="E4" events="6" subjects_affected="6" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" events="21" subjects_affected="17" subjects_at_risk="292"/>
                <counts group_id="E2" events="15" subjects_affected="13" subjects_at_risk="289"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="159"/>
                <counts group_id="E4" events="7" subjects_affected="7" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="17" subjects_affected="16" subjects_at_risk="292"/>
                <counts group_id="E2" events="20" subjects_affected="20" subjects_at_risk="289"/>
                <counts group_id="E3" events="9" subjects_affected="8" subjects_at_risk="159"/>
                <counts group_id="E4" events="9" subjects_affected="9" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="29" subjects_affected="27" subjects_at_risk="292"/>
                <counts group_id="E2" events="27" subjects_affected="27" subjects_at_risk="289"/>
                <counts group_id="E3" events="12" subjects_affected="11" subjects_at_risk="159"/>
                <counts group_id="E4" events="23" subjects_affected="19" subjects_at_risk="149"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="50" subjects_affected="46" subjects_at_risk="292"/>
                <counts group_id="E2" events="46" subjects_affected="43" subjects_at_risk="289"/>
                <counts group_id="E3" events="31" subjects_affected="28" subjects_at_risk="159"/>
                <counts group_id="E4" events="24" subjects_affected="23" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Dysphonia</sub_title>
                <counts group_id="E1" events="18" subjects_affected="17" subjects_at_risk="292"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="289"/>
                <counts group_id="E3" events="7" subjects_affected="5" subjects_at_risk="159"/>
                <counts group_id="E4" events="6" subjects_affected="6" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="84" subjects_affected="66" subjects_at_risk="292"/>
                <counts group_id="E2" events="71" subjects_affected="60" subjects_at_risk="289"/>
                <counts group_id="E3" events="61" subjects_affected="43" subjects_at_risk="159"/>
                <counts group_id="E4" events="43" subjects_affected="38" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="34" subjects_affected="32" subjects_at_risk="292"/>
                <counts group_id="E2" events="13" subjects_affected="11" subjects_at_risk="289"/>
                <counts group_id="E3" events="21" subjects_affected="19" subjects_at_risk="159"/>
                <counts group_id="E4" events="6" subjects_affected="5" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" events="25" subjects_affected="20" subjects_at_risk="292"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="289"/>
                <counts group_id="E3" events="15" subjects_affected="10" subjects_at_risk="159"/>
                <counts group_id="E4" events="9" subjects_affected="8" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="292"/>
                <counts group_id="E2" events="8" subjects_affected="6" subjects_at_risk="289"/>
                <counts group_id="E3" events="9" subjects_affected="8" subjects_at_risk="159"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="21" subjects_affected="20" subjects_at_risk="292"/>
                <counts group_id="E2" events="15" subjects_affected="13" subjects_at_risk="289"/>
                <counts group_id="E3" events="14" subjects_affected="12" subjects_at_risk="159"/>
                <counts group_id="E4" events="12" subjects_affected="11" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Productive cough</sub_title>
                <counts group_id="E1" events="11" subjects_affected="9" subjects_at_risk="292"/>
                <counts group_id="E2" events="11" subjects_affected="9" subjects_at_risk="289"/>
                <counts group_id="E3" events="9" subjects_affected="8" subjects_at_risk="159"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="149"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" events="20" subjects_affected="17" subjects_at_risk="292"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="289"/>
                <counts group_id="E3" events="32" subjects_affected="29" subjects_at_risk="159"/>
                <counts group_id="E4" events="36" subjects_affected="36" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Dermatitis acneiform</sub_title>
                <counts group_id="E1" events="444" subjects_affected="223" subjects_at_risk="292"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="289"/>
                <counts group_id="E3" events="160" subjects_affected="100" subjects_at_risk="159"/>
                <counts group_id="E4" events="5" subjects_affected="4" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" events="70" subjects_affected="62" subjects_at_risk="292"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="289"/>
                <counts group_id="E3" events="34" subjects_affected="27" subjects_at_risk="159"/>
                <counts group_id="E4" events="7" subjects_affected="7" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" events="13" subjects_affected="12" subjects_at_risk="292"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="289"/>
                <counts group_id="E3" events="12" subjects_affected="9" subjects_at_risk="159"/>
                <counts group_id="E4" events="7" subjects_affected="7" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Nail disorder</sub_title>
                <counts group_id="E1" events="20" subjects_affected="17" subjects_at_risk="292"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" events="8" subjects_affected="8" subjects_at_risk="159"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="36" subjects_affected="30" subjects_at_risk="292"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="289"/>
                <counts group_id="E3" events="16" subjects_affected="13" subjects_at_risk="159"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="35" subjects_affected="20" subjects_at_risk="292"/>
                <counts group_id="E2" events="38" subjects_affected="32" subjects_at_risk="289"/>
                <counts group_id="E3" events="10" subjects_affected="8" subjects_at_risk="159"/>
                <counts group_id="E4" events="13" subjects_affected="12" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Skin disorder</sub_title>
                <counts group_id="E1" events="33" subjects_affected="24" subjects_at_risk="292"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" events="17" subjects_affected="13" subjects_at_risk="159"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="149"/>
              </event>
              <event>
                <sub_title>Skin fissures</sub_title>
                <counts group_id="E1" events="22" subjects_affected="15" subjects_at_risk="292"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="289"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="159"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="149"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="34" subjects_affected="29" subjects_at_risk="292"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="289"/>
                <counts group_id="E3" events="17" subjects_affected="15" subjects_at_risk="159"/>
                <counts group_id="E4" events="11" subjects_affected="11" subjects_at_risk="149"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Chief Medical Officer</name_or_title>
      <organization>Eli Lilly and Company</organization>
      <phone>800-545-5979</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

